Sebetralstat enabled prompt treatment of laryngeal HAE attacks with median time of 1 hour and 16 minutes to onset of symptom relief– –Pooled data analysis showed adolescents treated with ...

Links to all presentations can be found on the KalVista website under Publications. About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment ...

Sebetralstat is a novel oral plasma kallikrein inhibitor aimed at treating HAE attacks in adults and adolescents aged 12 and older. The drug has also been submitted for regulatory review by the U ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...

SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shared new data at the AAAAI/WAO 2025 Joint Congress, indicating their investigational drug sebetralstat could significantly ...

SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The company has also submitted a new drug application ...

In other recent news, KalVista Pharmaceuticals has been making significant strides in the development of sebetralstat, a potential game-changer in the treatment of hereditary angioedema (HAE). The ...

Participants receiving LTP treated 382 attacks with sebetralstat (mean 1.7 attacks per month), of which more than half involved the abdomen and/or larynx. Sebetralstat enabled early treatment ...

Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S (#L15): Jonathan Bernstein, Emel Aygoren-Pursun, Vesna ...